Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Takeda

Drug Profile

Immune globulin - Takeda

Alternative Names: 10% HyQ; 20% SubQ; CUVITRU; Cuvitru; Gammagard Liquid; Gammagard S/D; Human Immune Globulin for Subcutaneous Administration; HyQ; HyQvia; Ig20Gly; IGI 10% with rHuPH20; IGIV - Baxalta; IGSC - Baxalta; immune globulin intravenous; IVIG 10%; Kiovig; SCIG 20%; SHP-671; TAK 771; TAK-339; TAK-664; TAK-881

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Baxter International; Halozyme Therapeutics; Shire; Takeda
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy; Peripheral nervous system diseases
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allotransplant rejection; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Ataxia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Jan 2024 Registered for Chronic inflammatory demyelinating polyradiculoneuropathy in USA (IV)
  • 29 Jan 2024 Efficacy and adverse events data from ADVANCE-CIDP 2 phase III trial released by Takeda
  • 16 Jan 2024 Registered for Chronic inflammatory demyelinating polyradiculoneuropathy in European Union, Norway, Iceland, Liechtenstein (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top